AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound represented by the formula (I):

wherein R7 and R21, the same or different, represent

- 1) a C2 to C22 alkoxy group which may have a substituent,
- 2) an unsaturated C2 to C22 alkoxy group which may have a substituent,
- 3) a C7 to C22 aralkyloxy group which may have a substituent,
- 4) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,
- 5) RC(=Y)-O-, wherein Y represents an oxygen atom or sulfur atom, and R represents
 - a) a hydrogen atom.
 - b) a C2 to C22 alkyl group which may have a substituent,
 - c) an unsaturated C2 to C22 alkyl group which may have a substituent,
 - d) a C6 to C14 arvl group which may have a substituent.
 - e) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - f) a C7 to C22 aralkyl group which may have a substituent.
 - g) a 5-membered to 14-membered heteroaralkyl group which may have a

substituent,

h) a C1 to C22 alkoxy group which may have a substituent,

i) an unsaturated C2 to C22 alkoxy group which may have a substituent,

j) a C6 to C14 aryloxy group which may have a substituent,

k) a C3 to C14 cycloalkyl group which may have a substituent,

I) a 3-membered to 14-membered non-aromatic heterocyclic group which may

have a substituent or

m) a 5-membered to 14-membered heteroaryloxy group which may have a

substituent,

6) RS1RS2RS3SiO-, wherein RS1, RS2 and RS3, the same or different, represent

a) a C1 to C6 alkyl group or

b) a C₆ to C₁₄ aryl group,

7) a halogen atom,

8) RNIRN2N-RM-, wherein RM represents

a) a single bond,

b) -CO-O-.

c) -SO2-O-,

d) -CS-O- or

e) -CO-NR^{N3}-, wherein R^{N3} represents a hydrogen atom or a C₁ to C₆ alkyl group

which may have a substituent, provided that, the leftmost bond in b) to e) is bonded to the

nitrogen atom, and

RN1 and RN2, the same or different, represent

4

Amendment dated November 8, 2007 Reply to Office Action of June 8, 2007

a) a hydrogen atom.

a) a hydrogen atom,

b) a C1 to C22 alkyl group which may have a substituent,

c) an unsaturated C2 to C22 alkyl group which may have a substituent,

d) an aliphatic C2 to C22 acyl group which may have a substituent,

e) an aromatic C7 to C15 acyl group which may have a substituent,

f) a C6 to C14 aryl group which may have a substituent,

g) a 5-membered to 14-membered heteroaryl group which may have a substituent,

h) a C7 to C22 aralkyl group which may have a substituent,

i) a C1 to C22 alkylsulfonyl group which may have a substituent,

j) a C6 to C14 arylsulfonyl group which may have a substituent,

k) a 3-membered to 14-membered non-aromatic heterocyclic group formed by

 R^{N1} and R^{N2} together in combination with the nitrogen atom to which R^{N1} and R^{N2} are bonded,

wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a

substituent.

l) a 5-membered to 14-membered heteroaralkyl group which may have a

substituent,

m) a C₃ to C₁₄ cycloalkyl group which may have a substituent or

n) a 3-membered to 14-membered non-aromatic heterocyclic group which may

have a substituent.

9) $R^{N4}SO_2$ -O-, wherein R^{N4} represents

a) a C1 to C22 alkyl group which may have a substituent,

b) a C_6 to C_{14} aryl group which may have a substituent, $\label{eq:condition} 5$

- c) a C1 to C22 alkoxy group which may have a substituent,
- d) an unsaturated C2 to C22 alkoxy group which may have a substituent,
- e) a C6 to C14 aryloxy group which may have a substituent,
- f) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,
 - g) a C7 to C22 aralkyloxy group which may have a substituent or
- h) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent.
- 10) (RN5O)2PO-O-, wherein RN5 represents
 - a) a C1 to C22 alkyl group which may have a substituent,
 - b) an unsaturated C2 to C22 alkyl group which may have a substituent,
 - c) a C6 to C14 aryl group which may have a substituent,
 - d) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - e) a C_7 to C_{22} aralkyl group which may have a substituent or
- f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent
- 11) (RN1RN2N)2PO-O-, wherein RN1 and RN2 are the same as defined above or

6

12) (R^{NI}R^{N2}N)(R^{N5}O)PO-O-, wherein R^{N1}, R^{N2} and R^{N5} are the same as defined above; or a pharmacologically acceptable salt thereof, or a hydrate of those.

2. (Currently Amended) The compound according to claim 1 represented by the formula (I-a):

Docket No.: 0152-0701PUS1

wherein R7a and R21a, the same or different, represent

- 1) a C2 to C22 alkoxy group which may have a substituent,
- 2) an unsaturated C2 to C22 alkoxy group which may have a substituent,
- 3) a C7 to C22 aralkyloxy group which may have a substituent,
- 4) RaC(=Ya)-O-, wherein Ya represents an oxygen atom or sulfur atom, and Ra represents
 - a) a hydrogen atom,
 - b) a C2 to C22 alkyl group which may have a substituent,
 - c) an unsaturated C2 to C22 alkyl group which may have a substituent,
 - d) a C6 to C14 aryl group which may have a substituent,
 - e) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - f) a C7 to C22 aralkyl group which may have a substituent,
 - g) a 5-membered to 14-membered heteroaralkyl group which may have a

substituent,

h) a C1 to C22 alkoxy group which may have a substituent,

7

Amendment dated November 8, 2007 Reply to Office Action of June 8, 2007

i) an unsaturated C2 to C22 alkoxy group which may have a substituent,

i) a C6 to C14 aryloxy group which may have a substituent or

k) a 3-membered to 14-membered heteroaryloxy group which may have a

substituent.

5) RaN1RaN2N-CO-O-, wherein RaN1 and RaN2, the same or different, represent

a) a hydrogen atom,

b) a C1 to C22 alkyl group which may have a substituent,

c) an unsaturated C2 to C22 alkyl group which may have a substituent.

d) a C6 to C14 aryl group which may have a substituent,

e) a 5-membered to 14-membered heteroaryl group which may have a substituent,

f) a C7 to C22 aralkyl group which may have a substituent,

g) a 3-membered to 14-membered non-aromatic heterocyclic group formed by

RaN1 and RaN2 together in combination with the nitrogen atom to which RaN1 and RaN2 are

bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a

substituent.

h) a 5-membered to 14-membered heteroaralkyl group which may have a

substituent.

i) a C3 to C14 cycloalkyl group which may have a substituent or

i) a 3-membered to 14-membered non-aromatic heterocyclic group which may

have a substituent.

6) RaNI RaN2 N-SO2-O-, wherein RaNI and RaN2 are the same as defined above.

7) RaNI RaN2 N-CS-O-, wherein RaN1 and RaN2 are the same as defined above.

8

Amendment dated November 8, 2007 Reply to Office Action of June 8, 2007

8) RaN4SO2-O-, wherein RaN4 represents

- a) a C1 to C22 alkyl group which may have a substituent,
- b) a C6 to C14 aryl group which may have a substituent,
- c) a C1 to C22 alkoxy group which may have a substituent,
- d) an unsaturated C2 to C22 alkoxy group which may have a substituent,
- e) a C6 to C14 aryloxy group which may have a substituent,
- f) a 5-membered to 14-membered heteroaryloxy group which may have a substituent.
 - g) a C₇ to C₂₂ aralkyloxy group which may have a substituent or
- h) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,
- 9) $(R^{aN5}O)_2PO$ -O-, wherein R^{aN5} represents
 - a) a C_1 to C_{22} alkyl group which may have a substituent,
 - b) an unsaturated C2 to C22 alkyl group which may have a substituent,
 - c) a C6 to C14 aryl group which may have a substituent,
 - d) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - e) a C7 to C22 aralkyl group which may have a substituent or
- f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent.
- 10) (RaNIRaN2N)2-PO-O-, wherein RaN1 and RaN2 are the same as defined above or
- 11) (R^{aNI} R^{aN2}N)(R^{aN5}O)PO-O-, wherein R^{aNI}, R^{aN2} and R^{aN5} are the same as defined above; or a pharmacologically acceptable salt thereof₅-or a hydrate of those.

- 3. (Currently Amended) The compound according to claim 1, wherein R⁷ and/or R²¹ represent a C₇ to C₂₂ aralkyloxy group which may have a substituent, RC(=Y)-O-, wherein Y and R are the same as defined above or R^{N1}R^{N2}N-R^M-, wherein R^M represents
 - a) -CO-O- or
- b) -CS-O-, and R^{NI} and R^{NZ} are the same as defined above, provided that, the leftmost bond in a) and b) is bonded to the nitrogen atom; or a pharmacologically acceptable salt thereof, or a hydrate of those.
- 4. (Currently Amended) The compound according to claim 1, wherein R^{N1} and R^{N2}, the same or different, represent a C₁ to C₆ alkyl group or C₆ to C₁₄ aryl group, or form, together in combination with the nitrogen atom to which R^{N1} and R^{N2} are bonded, a non-aromatic heterocyclic group selected from the group consisting of:

or a pharmacologically acceptable salt thereof, or a hydrate of those.

 (Currently Amended) The compound according to claim 2 represented by the formula (I-b):

wherein R^{7b} and R^{21b} , the same or different, represent a C_7 to C_{22} aralkyloxy group which may have a substituent, or R^b -C(= Y^b)-O-, wherein Y^b represents an oxygen atom or sulfur atom, and R^b , the same or different, represents

- a) a hydrogen atom,
- b) a C2 to C6 alkyl group which may have a substituent,
- c) a C6 to C14 aryl group which may have a substituent,
- d) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- e) a C₇ to C₁₀ aralkyl group which may have a substituent,
- f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- g) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
 - h) a group of the formula (III):

Docket No.: 0152-0701PUS1

wherein A) n represents an integer of 0 to 4,

Xh represents

- i) -CHRbN4-,
- ii) -NR^{bN5}-.
- iii) -O-,
- iv) -S-,
- v) -SO- or
- vi) -SO2-,

RbN1 represents

- i) a hydrogen atom or
- ii) a C₁ to C₆ alkyl group which may have a substituent,

R^{bN2} represents

- i) a hydrogen atom or
- ii) a C1 to C6 alkyl group which may have a substituent,

R^{bN3} and R^{bN4}, the same or different, represent

- i) a hydrogen atom,
- ii) a C1 to C6 alkyl group which may have a substituent,
- iii) an unsaturated C2 to C10 alkyl group which may have a substituent,

- iv) a C6 to C14 aryl group which may have a substituent,
- v) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- vi) a C7 to C10 aralkyl group which may have a substituent,
- vii) a C3 to C8 cycloalkyl group which may have a substituent,
- viii) a C4 to C9 cycloalkylalkyl group which may have a substituent,
- ix) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- xi) $-NR^{bN6}R^{bN7}$, wherein R^{bN6} and R^{bN7} , the same or different, represent a hydrogen atom or a C_1 to C_6 alkyl group which may have a substituent or
- xii) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN3} and R^{bN4} together in combination with the carbon atom to which R^{bN3} and R^{bN4} are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and

R^{bN5} represents

- i) a hydrogen atom,
- ii) a C1 to C6 alkyl group which may have a substituent.
- iii) an unsaturated C2 to C10 alkyl group which may have a substituent,
- iv) a C6 to C14 arvl group which may have a substituent,
- v) a 5-membered to 14-membered heteroaryl group which may have a substituent.
- vi) a C₇ to C₁₀ aralkyl group which may have a substituent,

13

Docket No.: 0152-0701PUS1

Amendment dated November 8, 2007

Application No. 10/522,733

Reply to Office Action of June 8, 2007

vii) a C3 to C8 cycloalkyl group which may have a substituent,

viii) a C4 to C9 cycloalkylalkyl group which may have a substituent.

ix) a 5-membered to 14-membered heteroaralkyl group which may have a

substituent.

x) a 5-membered to 14-membered non-aromatic heterocyclic group which may

have a substituent or

xi) a 5-membered to 14-membered non-aromatic heterocyclic group formed by

RbN3 and RbN5 together in combination with the nitrogen atom to which RbN3 and RbN5 are

bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a

substituent,

B)

X_b, n, R^{bN3}, R^{bN4} and R^{bN5} represent the same group as defined above, and R^{bN1}

and R^{bN2} represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by

R^{bNI} and R^{bN2} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic

group may have a substituent,

C)

Xb, n, RbN2, RbN4 and RbNn5 represent the same group as defined above, and RbN1

and RbN3 represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by

RbN1 and RbN3 together, wherein the 5-membered to 14-membered non-aromatic heterocyclic

group may have a substituent or

D)

X_{b.} n. R^{bN1}. R^{bN4} and R^{bN5} represent the same group as defined above, and R^{bN2}

Docket No : 0152-0701PUS1

Application No. 10/522,733 Amendment dated November 8, 2007 Reply to Office Action of June 8, 2007

and R^{bN3} represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN2} and R^{bN3} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

i) a group of the formula (IV):

wherein R^{bN8} and R^{bN9} , the same or different, represent

- i) a hydrogen atom,
- ii) a C1 to C6 alkyl group which may have a substituent,
- iii) a C6 to C14 aryl group which may have a substituent,
- iv) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - v) a C7 to C10 aralkyl group which may have a substituent or
- vi) a 5-membered to 14-membered heteroaralkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.
- (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{al}C(=Y^{al})-O-, wherein Y^{al} represents an oxygen atom or sulfur atom, and R^{al} represents

15

1) a hydrogen atom,

2) a C2 to C6 alkyl group which may have a substituent,

3) a C₆ to C₁₀ aryl group which may have a substituent,

4) a 5-membered to 14-membered heteroaryl group which may have a substituent,

5) a C7 to C10 aralkyl group which may have a substituent or

6) a 5-membered to 14-membered heteroaralkyl group which may have a substituent; or a pharmacologically acceptable salt thereof-or-a-hydrate-of-those.

7. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R⁴²C(=Y^{a2})-O-, wherein Y^{a2} represents an oxygen atom or sulfur atom, and R⁴² represents a group of the formula (III'):

$$R^{aN8} \xrightarrow{X_1} \bigcap_{\substack{n \\ kaN6}}^{R^{aN7}} (III')$$

wherein A) n represents an integer of 0 to 4,

X₁ represents

- 1) -CHR^{aN9}-,
- 2) -NR^{aN10}-,
- 3) -0-,
- 4) -S-,
- 5) -SO- or

6) -SO₂-,

RaN6 and RaN7, the same or different, represent

- 1) a hydrogen atom or
- 2) a C1 to C6 alkyl group which may have a substituent,

RaN8 and RaN9, the same or different, represent

- 1) a hydrogen atom,
- 2) a C1 to C6 alkyl group which may have a substituent,
- 3) an unsaturated C2 to C10 alkyl group which may have a substituent,
- 4) a C6 to C14 aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

Docket No.: 0152-0701PUS1

- 6) a C₇ to C₁₀ aralkyl group which may have a substituent,
- 7) a C2 to C2 evcloalkyl group which may have a substituent,
- 8) a C4 to C9 cycloalkylalkyl group which may have a substituent.
- a 5-membered to 14-membered heteroaralkyl group which may have a substituent.
- a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- 11) -NR aN12 R aN12 , wherein R aN11 and R aN12 , the same or different, represent a hydrogen atom or a C_1 to C_6 alkyl group which may have a substituent or
- 12) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{aN8} and R^{aN9} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and

RaN10 represents

substituent.

1) a hydrogen atom,

2) a C1 to C6 alkyl group which may have a substituent,

3) an unsaturated C2 to C10 alkyl group which may have a substituent,

4) a C6 to C14 aryl group which may have a substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C7 to C10 aralkyl group which may have a substituent,

7) a C3 to C8 cycloalkyl group which may have a substituent.

8) a C4 to C9 cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a

10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent.

11) a 5-membered to 14-membered non-aromatic heterocyclic group formed by

the nitrogen atom to which R^{aN10} is bonded, and one substituent selected from the group consisting of R^{aN6}, R^{aN7} and R^{aN8} together, wherein the 5-membered to 14-membered non-

consisting of it, it und it together, wholein the 5 membered to 11 membered not

aromatic heterocyclic group may have a substituent or

12) a 5-membered to 14-membered non-aromatic heterocyclic group formed by

the nitrogen atom to which R^{aN10} is bonded, and two substituents selected from the group

consisting of R^{aN6} , R^{aN7} and R^{aN8} together, wherein the 5-membered to 14-membered non-

aromatic heterocyclic group may have a substituent or

B) n, X_1 , R^{aN7} , R^{aN9} and R^{aN10} represent the same group as defined above, and R^{aN6} and R^{aN8}

18

represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{aN6} and R^{aN8} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent; or a pharmacologically acceptable salt thereof_x-ox a hydrate of those.

- 8. (Currently Amended) The compound according to claim [[6]] $\underline{7}$, wherein X_1 represents -NR^{aN10}, wherein NR^{aN10} is the same as defined above; or a pharmacologically acceptable salt thereof₇ or a hydrate of those.
- 9. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a3}C(=Y^{a3})-O-, wherein Y^{a3} represents an oxygen atom or sulfur atom, and R^{a3} represents a group of the formula (V):

$$R^{aN14} \underset{h}{\underbrace{\hspace{1cm}}} N^{2} \underset{haN13}{\underbrace{\hspace{1cm}}} (V)$$

wherein n represents an integer of 0 to 4,

RaN13 represents

- 1) a hydrogen atom or
- 2) a C1 to C6 alkyl group which may have a substituent, and

RaN14 represents

- 1) a hydrogen atom,
- 2) an amino group which may have a substituent,

3) a pyridinyl group which may have a substituent,

4) a pyrrolidin-1-yl group which may have a substituent,

5) a piperidin-1-yl group which may have a substituent,

6) a morpholin-4-yl group which may have a substituent or

 a piperazin-1-yl group which may have a substituent; or a pharmacologically acceptable salt thereof-or a hydrate of those.

10. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{84} CO-O-, wherein R^{84} represents a group of the formula (VI):

$$\begin{array}{c}
R^{aN16} \\
\downarrow \\
N_1 \\
N_2 \\
\downarrow \\
N_2 \\
\downarrow \\
N_{aN15}
\end{array}$$
(VI)

wherein $\ensuremath{n_1}$ and $\ensuremath{n_2}$, the same or different, represent an integer of 0 to 4,

 X_2 represents

- 1) -CHR^{aN17}-,
- 2) -NR^{aN18}-,
- 3) -O-,
- 4) -S-,
- 5) -SO- or
- 6) -SO2-.

RaN15 represents

- 1) a hydrogen atom or
- 2) a C1 to C6 alkyl group which may have a substituent,

RaN16 represents

- 1) a hydrogen atom,
- 2) a C1 to C6 alkyl group which may have a substituent,
- 3) a C6 to C14 aryl group which may have a substituent or
- 4) a C7 to C10 aralkyl group which may have a substituent,

RaN17 represents

- a hydrogen atom,
 - 2) a C1 to C6 alkyl group which may have a substituent,
 - 3) an unsaturated C2 to C10 alkyl group which may have a substituent,
 - 4) a C6 to C14 aryl group which may have a substituent,
 - 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - 6) a C₇ to C₁₀ aralkyl group which may have a substituent,
 - 7) a C3 to C8 cycloalkyl group which may have a substituent,
 - a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- 10) -NR^{aN19}R^{aN20}, wherein R^{aN19} and R^{aN20}, the same or different, represent a hydrogen atom or a C_1 to C_6 alkyl group which may have a substituent or
 - 11) a 5-membered to 14-membered non-aromatic heterocyclic group which may

have a substituent, and

RaN18 represents

- 1) a hydrogen atom,
- 2) a C1 to C6 alkyl group which may have a substituent,
- 3) an unsaturated C2 to C10 alkyl group which may have a substituent,
- 4) a C6 to C14 aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C₇ to C₁₀ aralkyl group which may have a substituent,
- 7) a C3 to C8 cycloalkyl group which may have a substituent,
- 8) a C4 to C9 cycloalkylalkyl group which may have a substituent,
- a 5-membered to 14-membered heteroaralkyl group which may have a substituent or
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.
- 11. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R⁴⁵CO-O-, wherein R^{a5} represents a group of the formula (VII):

wherein n3 represents 1 or 2,

Docket No : 0152-0701PUS1

Amendment dated November 8, 2007 Reply to Office Action of June 8, 2007

RaN21 represents

1) a hydrogen atom or

2) a C1 to C6 alkyl group which may have a substituent, and

R^{aN22} represents

- 1) a hydrogen atom or
- a C₁ to C₆ alkyl group which may have a substituent; or a pharmacologically acceptable salt thereof₇ or a hydrate of those.
- 12. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a6} CO-O-, wherein R^{a6} represents a group of the formula (VIII):

wherein n_1 and n_2 , the same or different, represent an integer of 0 to 4,

X₃ represents

- 1) -CHR^{aN25}-,
- 2) -NR^{aN26}-,
- 3) -O-,
- 4) -S-,
- 5) -SO- or

Docket No : 0152-0701PUS1

6) -SO2-,

RaN23 represents

- 1) a hydrogen atom or
- 2) a C1 to C6 alkyl group which may have a substituent.

RaN24 represents

- 1) a hydrogen atom,
- 2) a C1 to C6 alkyl group which may have a substituent,
- 3) a C6 to C14 aryl group which may have a substituent or
- 4) a C7 to C10 aralkyl group which may have a substituent.

RaN25 represents

- 1) a hydrogen atom,
- 2) a C1 to C6 alkyl group which may have a substituent.
- 3) an unsaturated C2 to C10 alkyl group which may have a substituent,
- 4) a C1 to C6 alkoxy group which may have a substituent,
- 5) a C6 to C14 arvl group which may have a substituent.
- 6) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 7) a C7 to C10 aralkyl group which may have a substituent.
- 8) a C₃ to C₈ cycloalkyl group which may have a substituent,
- 9) a C4 to C9 cycloalkylalkyl group which may have a substituent,
- a 5-membered to 14-membered heteroaralkyl group which may have a substituent.
 - 11) -NRaN27RaN28, wherein RaN27 and RaN28, the same or different, represent a

hydrogen atom or a C1 to C6 alkyl group which may have a substituent or

12) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, and

RaN26 represents

- 1) a hydrogen atom,
- 2) a C1 to C6 alkyl group which may have a substituent,
- 3) an unsaturated C2 to C10 alkyl group which may have a substituent,
- 4) a C6 to C14 arvl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C₇ to C₁₀ aralkyl group which may have a substituent,
- 7) a C3 to C8 cycloalkyl group which may have a substituent,
- 8) a C4 to Co cycloalkylalkyl group which may have a substituent.
- a 5-membered to 14-membered heteroaralkyl group which may have a substituent or
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or a pharmacologically acceptable salt thereof-or-a-hydrate-of-those.
- 13. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a7} CO-O-, wherein R^{a7} represents a group of the formula (IX):

wherein n_4 represents an integer of 1 to 3, and R^{aN29} represents

- 1) an amino group which may have a substituent,
 - 2) a pyrrolidin-1-yl group which may have a substituent,
 - 3) a piperidin-1-yl group which may have a substituent or
- a morpholin-4-yl group which may have a substituent; or a pharmacologically acceptable salt thereof-or-a-hydrate-of-those.
- 14. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a8}CO-O-, wherein R^{a8} represents a group of the formula (X):

$$R^{aN30}$$
 $N \longrightarrow S$
 (X)

wherein n4 represents an integer of 1 to 3,

RaN30 represents

- 1) a hydrogen atom,
- 2) a C1 to C6 alkyl group which may have a substituent,
- 3) a C6 to C14 aryl group which may have a substituent or
- 4) a C7 to C10 aralkyl group which may have a substituent, and

Amendment dated November 8, 2007 Reply to Office Action of June 8, 2007

RaN31 represents

1) a hydrogen atom,

2) a C1 to C6 alkyl group which may have a substituent,

3) a C3 to C8 cycloalkyl group which may have a substituent,

 a 3-membered to 8-membered non-aromatic heterocyclic group which may have a substituent,

5) a C₆ to C₁₄ aryl group which may have a substituent,

6) a 5-membered to 14-membered heteroaryl group which may have a substituent,

7) a C7 to C10 aralkyl group which may have a substituent,

8) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or

9) a C₄ to C₉ cycloalkylalkyl group which may have a substituent; or a pharmacologically acceptable salt thereof₇-or a hydrate of those.

15. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a0}CO-O-, wherein R^{a0} represents a group of the formula (XI):

$$\mathbb{R}^{aN32}$$
, \mathbb{N} \mathbb{N} \mathbb{N} \mathbb{N} \mathbb{N}

wherein n_4 represents an integer of 1 to 3, and $R^{aN32} \mbox{ represents}$

Amendment dated November 8, 2007 Reply to Office Action of June 8, 2007

1) a hydrogen atom,

2) a C1 to C6 alkyl group which may have a substituent,

3) a C3 to C8 cycloalkyl group which may have a substituent,

4) a C4 to C9 cycloalkylalkyl group which may have a substituent,

5) a C7 to C10 aralkyl group which may have a substituent,

6) a pyridyl group which may have a substituent or

 a tetrahydropyranyl group which may have a substituent; or a pharmacologically acceptable salt thereof; or a hydrate of those.

16. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a10} CO-O-, wherein R^{a10} represents a group of the formula (XII):

$$m_2$$
 m_1
 m_2
 m_1
 m_2
 m_3
 m_4
 m_4

wherein $m_1,\,m_2,\,m_3$ and $m_4,$ the same or differently, represent 0 or 1,

n4 represents an integer of 1 to 3, and

RaN33 represents

- 1) a hydrogen atom,
- 2) a C1 to C6 alkyl group which may have a substituent,
- 3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,

- 4) a C6 to C14 aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C7 to C10 aralkyl group which may have a substituent,
- 7) a C3 to C8 cycloalkyl group which may have a substituent,
- 8) a C4 to C9 cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.
- 17. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a11}CO-O-, wherein R^{a11} represents a group of the formula (XIII):

$$m_{\delta} (N_{\gamma})_{n_{\delta}} (XIII)$$

wherein m_5 represents an integer of 1 to 3, and n_5 represents 2 or 3; or a pharmacologically acceptable salt thereof₇ or a hydrate of those.

18. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a12}CO-O-, wherein R^{a12} represents a group selected from a group consisting of:

or a group selected from a group consisting of

and both of which may have a substituent on the ring;

or a pharmacologically acceptable salt thereof, or a hydrate of those.

19. (Currently Amended) The compound according to claim 1, which is (8E,12E,14E)-21-benzoyloxy-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricosa-8,12,14-trien-11-olide,

(8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-21-N,N-dimethylcarbamoyloxy-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricosa-8,12,14-trien-11-olide and

(8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-

Amendment dated November 8, 2007 Reply to Office Action of June 8, 2007

 $yl) carbonyl) oxy-21-phenyl carbamoyl oxy-18, 19-epoxytricosa-8, 12, 14-trien-11-olide; \qquad or \qquad a$

pharmacologically acceptable salt thereof, or a hydrate of those.

20. (Cancelled)

21. (Currently Amended) A pharmaceutical composition comprising the compound

according to claim 1, or a pharmacologically acceptable salt thereof, or a hydrate of those as an

active ingredient and a pharmaceutically acceptable carrier.

22-45. (Cancelled)